These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24279137)

  • 1. [Edoxaban is safer than vitamin K antagonists].
    Einecke D
    MMW Fortschr Med; 2013 Sep; 155(16):20. PubMed ID: 24279137
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
    Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
    J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are direct oral anticoagulants such as edoxaban safer than heparin or vitamin K-antagonists when intracranial hemorrhage occurs?
    Dempfle CE
    Thromb Res; 2014 Apr; 133(4):521-2. PubMed ID: 24568776
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.
    Ohmori H; Nakamura M; Kada A; Saito AM; Sanayama Y; Shinagawa T; Fujita H; Wakisaka A; Maruhashi K; Okumura A; Takizawa N; Murata H; Inoue M; Kaneko H; Taniguchi H; Kawasaki M; Sano N; Akaboshi S; Tanuma N; Sone S; Kumode M; Takechi T; Koretsune Y; Sumimoto R; Miyanomae T
    Kurume Med J; 2018 Dec; 65(1):11-16. PubMed ID: 30158356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 7. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation and Renal Insufficiency.
    Koulouri A; Calanca L; Mazzolai L
    Ther Umsch; 2016; 73(10):567-572. PubMed ID: 28045357
    [No Abstract]   [Full Text] [Related]  

  • 10. Another novel oral anticoagulant matches warfarin.
    Mitka M
    JAMA; 2014 Jan; 311(3):233-4. PubMed ID: 24430308
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
    Shirley M; Dhillon S
    Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The ENGAGE AF-TIMI 48 study].
    Rubboli A; Colonna P
    G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
    [No Abstract]   [Full Text] [Related]  

  • 17. Edoxaban Was Effective for the Treatment of Deep Vein Thrombosis and Pulmonary Thromboembolism in a Cancer Patient with Antithrombin III Deficiency.
    Kawano H; Maemura K
    Intern Med; 2016; 55(22):3285-3289. PubMed ID: 27853070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Jan; 107(3):167-168. PubMed ID: 29382267
    [No Abstract]   [Full Text] [Related]  

  • 19. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.